Hhlr Advisors, Ltd. Arcus Biosciences, Inc. Transaction History

Hhlr Advisors, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $1.14 Million - $1.79 Million	-50,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $15 Million - $23.8 Million	-575,000 Reduced 92.0%	50,000 $1.4 Million
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $1.99 Million - $5.2 Million	-142,128 Reduced 18.53%	625,000 $15.5 Million
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $2.2 Million - $3.48 Million	342,128 Added 80.5%	767,128 $6.98 Million
Q4 2018 Feb 14, 2019	BUY	$9.74 - $14.5 $4.14 Million - $6.16 Million	425,000 New	425,000 $4.58 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.